Scarica l'app Stockscreener
12.29
11.73%
1.29
Dopo l'orario di chiusura:
11.85
-0.44
-3.58%
Precedente Chiudi:
$11.00
Aprire:
$11.82
Volume 24 ore:
148.35K
Relative Volume:
4.56
Capitalizzazione di mercato:
$25.51M
Reddito:
-
Utile/perdita netta:
$-4.85M
Rapporto P/E:
-39.65
EPS:
-0.31
Flusso di cassa netto:
$-3.95M
1 W Prestazione:
+23.77%
1M Prestazione:
+5.86%
6M Prestazione:
-11.33%
1 anno Prestazione:
+9.73%
Intervallo 1D:
$10.92
$12.50
Intervallo di 1 settimana:
$9.55
$12.50
Portata 52W:
$8.12
$22.90
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
Nome
Cadrenal Therapeutics Inc
Settore
Industria
Telefono
904-300-0701
Indirizzo
822 A1A NORTH, PONTE VEDRA
Confronta CVKD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
12.29 | 22.83M | 0 | -4.85M | -3.95M | -0.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-18 | Iniziato | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc Borsa (CVKD) Ultime notizie
Understanding the Setup: (CVKD) and Scalable Risk - news.stocktradersdaily.com
Cadrenal Therapeutics acquires VLX-1005 from Veralox - MSN
Cadrenal's Quiet Expansion Play Is Starting to Get Loud - The Joplin Globe
Cadrenal Therapeutics (NASDAQ: CVKD) adds HIT, Factor XIa drugs in quiet expansion - Stock Titan
Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market - ACCESS Newswire
Cadrenal Therapeutics (NASDAQ: CVKD) builds multi-asset anticoagulation platform in $40B market - Stock Titan
Cadrenal Therapeutics acquires late-stage drug assets from Maryland biotech - The Business Journals
Cadrenal Therapeutics acquires VLX-1005 for heparin-induced thrombocytopenia - TipRanks
Cadrenal Therapeutics acquires first-in-class HIT treatment from Veralox - Investing.com
Cadrenal Therapeutics Acquires VLX-1005 from Veralox - TipRanks
Cadrenal Therapeutics acquires first-in-class HIT treatment from Veralox By Investing.com - Investing.com Canada
Cadrenal Therapeutics acquires VLX-1005, a first-in-class Phase 2 12-LOX inhibitor for patients with heparin-induced thrombocytopenia - marketscreener.com
Cadrenal Therapeutics (Nasdaq: CVKD) adds Phase 2 12-LOX HIT therapy with FDA Fast Track - Stock Titan
Cadrenal Therapeutics (CVKD) Stock Analysis Report | Financials & Insights - Benzinga
Aug Gainers: Can Cadrenal Therapeutics Inc stock deliver strong Q4 earnings2025 Sector Review & Daily Momentum Trading Reports - moha.gov.vn
Is Cadrenal Therapeutics Inc. stock safe for conservative investorsGap Up & Weekly Market Pulse Updates - Newser
Why Cadrenal Therapeutics Inc. stock attracts global investorsGap Up & Fast Entry Momentum Trade Alerts - Newser
The Technical Signals Behind (CVKD) That Institutions Follow - news.stocktradersdaily.com
Can Cadrenal Therapeutics Inc. stock deliver strong Q4 earningsQuarterly Portfolio Summary & Daily Stock Trend Watchlist - Newser
Cadrenal Therapeutics, Inc. (CVKD) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Cadrenal Therapeutics appoints PTC Therapeutics CMO to board By Investing.com - Investing.com Australia
Cadrenal Therapeutics appoints Dr. Lee Golden to board of directors - marketscreener.com
Cadrenal Therapeutics Appoints Dr. Golden to Board - TipRanks
Cadrenal Therapeutics Appoints New Director - TradingView
Cadrenal Therapeutics, Inc. Appoints Dr. Lee Scott Golden to Board of Directors - Quiver Quantitative
Cadrenal Therapeutics appoints PTC Therapeutics CMO to board - Investing.com
Cadrenal Therapeutics, Inc. Appoints Lee Scott Golden, M.D. as Independent Director and Member of Science and Technology Committee - marketscreener.com
Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors - Sahm
Is Cadrenal Therapeutics Inc. stock affected by interest rate hikes2025 Risk Factors & Real-Time Volume Spike Alerts - BỘ NỘI VỤ
Cadrenal Therapeutics (CVKD) Stock Price, News & Analysis - MarketBeat
Will Cadrenal Therapeutics Inc. stock sustain high P E ratiosWeekly Investment Summary & Smart Allocation Stock Tips - BỘ NỘI VỤ
Precision Trading with Cadrenal Therapeutics Inc. (CVKD) Risk Zones - news.stocktradersdaily.com
Why Cadrenal Therapeutics Inc. stock could see breakout soonJuly 2025 Spike Watch & Growth Focused Stock Reports - newser.com
Institutional scanner results for Cadrenal Therapeutics Inc.2025 Earnings Impact & Step-by-Step Trade Execution Guides - newser.com
Is Cadrenal Therapeutics Inc. stock a good choice for value investors2025 Sector Review & Safe Entry Zone Tips - newser.com
Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida’s Executive of the Year Award - The Manila Times
Agilent Technologies (NYSE: A) Debuts Altura Ultra Inert HPLC With 2x Sensitivity - Stock Titan
Detecting price anomalies in Cadrenal Therapeutics Inc. with AITreasury Yields & Fast Gaining Stock Reports - newser.com
What the charts say about Cadrenal Therapeutics Inc. todayWatch List & Daily Stock Trend Watchlist - newser.com
Is Cadrenal Therapeutics Inc. stock attractive for retirement portfolios2025 Breakouts & Breakdowns & Risk Managed Investment Entry Signals - newser.com
Cadrenal Therapeutics Receives Legal Opinion From Blank Rome LLP On ?Validity Of Share Offering - MarketScreener
Cadrenal Therapeutics Announces New Stock Offering Program - TipRanks
Cadrenal Therapeutics IncBlank Rome LLP issued legal opinion on $3,438,062 sharesSEC filing - MarketScreener
[8-K] Cadrenal Therapeutics, Inc. Reports Material Event | CVKD SEC FilingForm 8-K - Stock Titan
Price momentum metrics for Cadrenal Therapeutics Inc. explainedDividend Hike & AI Forecast for Swing Trade Picks - newser.com
Quantitative breakdown of Cadrenal Therapeutics Inc. recent move2025 Major Catalysts & Growth Focused Entry Reports - newser.com
Cadrenal Therapeutics Inc Azioni (CVKD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):